Oxford BioMedica plc Stock Price, News & Analysis (LON:OXB)

GBX 8.50 0.10 (1.19 %)
(As of 11/20/2017 04:00 PM ET)
Previous CloseGBX 8.50
Today's RangeGBX 8.62 - GBX 8.31
52-Week RangeGBX 3.31 - GBX 11.25
Volume914,370 shs
Average Volume3.04 million shs
Market Capitalization£258.51 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Oxford BioMedica plc (LON:OXB)

Oxford BioMedica plc logoOxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: LON:OXB
  • CUSIP: N/A
  • Web: www.oxfordbiomedica.co.uk
Profitability:
  • Net Margins: -21.31%
  • Return on Equity: -56.98%
  • Return on Assets: -11.53%
Misc:
  • Outstanding Shares: 3,110,000,000
 

Frequently Asked Questions for Oxford BioMedica plc (LON:OXB)

What is Oxford BioMedica plc's stock symbol?

Oxford BioMedica plc trades on the London Stock Exchange (LON) under the ticker symbol "OXB."

Where is Oxford BioMedica plc's stock going? Where will Oxford BioMedica plc's stock price be in 2017?

3 Wall Street analysts have issued 1-year target prices for Oxford BioMedica plc's shares. Their predictions range from GBX 10.20 to GBX 13. On average, they expect Oxford BioMedica plc's stock price to reach GBX 12.07 in the next year. View Analyst Ratings for Oxford BioMedica plc.

Who are some of Oxford BioMedica plc's key competitors?

Who are Oxford BioMedica plc's key executives?

Oxford BioMedica plc's management team includes the folowing people:

  • John Dawson, Chief Executive Officer, Executive Director (Age 56)
  • Stuart Paynter, Chief Financial Officer, Director
  • Peter Nolan, Executive Director, Chief Business Officer (Age 62)
  • Lorenzo Tallarigo M.D., Non-Executive Chairman of the Board (Age 64)
  • Andrew J. Heath M.D., Ph.D., Non-Executive Deputy Chairman of the Board, Senior Independent Director (Age 66)
  • Martin Diggle, Non-Executive Director (Age 52)
  • Stuart Henderson, Non-Executive Director

How do I buy Oxford BioMedica plc stock?

Shares of Oxford BioMedica plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Oxford BioMedica plc's stock price today?

One share of Oxford BioMedica plc stock can currently be purchased for approximately GBX 8.50.

How big of a company is Oxford BioMedica plc?

Oxford BioMedica plc has a market capitalization of £258.51 million.

How can I contact Oxford BioMedica plc?

Oxford BioMedica plc's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1865-783000.


MarketBeat Community Rating for Oxford BioMedica plc (LON OXB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Oxford BioMedica plc (LON:OXB)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: GBX 12.07

Consensus Price Target History for Oxford BioMedica plc (LON:OXB)

Price Target History for Oxford BioMedica plc (LON:OXB)

Analysts' Ratings History for Oxford BioMedica plc (LON:OXB)

Show:
DateFirmActionRatingPrice TargetDetails
10/31/2017Peel HuntReiterated RatingBuyGBX 13View Rating Details
8/31/2017N+1 SingerBoost Price TargetHoldGBX 8.70 -> GBX 10.20View Rating Details
8/31/2017Jefferies Group LLCReiterated RatingBuyGBX 13View Rating Details
7/13/2017Shore CapitalReiterated Ratingnot ratedView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History for Oxford BioMedica plc (LON:OXB)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Oxford BioMedica plc (LON:OXB)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Oxford BioMedica plc (LON:OXB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Oxford BioMedica plc (LON OXB)

Insider Trades by Quarter for Oxford BioMedica plc (LON:OXB)

Insider Trades by Quarter for Oxford BioMedica plc (LON OXB)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/23/2017Lorenzo TallarigoInsiderBuy30,436GBX 9£2,739.24
9/26/2017Andrew HeathInsiderBuy110,511GBX 9£9,945.99
9/22/2017Lorenzo TallarigoInsiderBuy29,685GBX 9£2,671.65
9/15/2017Martin DiggleInsiderBuy100,000GBX 8£8,000
9/1/2017Martin DiggleInsiderBuy320,000GBX 9£28,800
8/31/2017Martin DiggleInsiderSell2,377,600GBX 10£237,760
7/17/2017Peter NolanInsiderBuy249,687GBX 8£19,974.96
7/13/2017Martin DiggleInsiderBuy660,000GBX 9£59,400
6/23/2017Lorenzo TallarigoInsiderBuy49,033GBX 5£2,451.65
5/24/2017Lorenzo TallarigoInsiderBuy53,260GBX 5£2,663
4/24/2017Lorenzo TallarigoInsiderBuy54,090GBX 5£2,704.50
3/23/2017Lorenzo TallarigoInsiderBuy49,468GBX 5£2,473.40
2/24/2017Lorenzo TallarigoInsiderBuy67,165GBX 4£2,686.60
12/15/2016Lorenzo TallarigoInsiderBuy65,993GBX 4£2,639.72
11/25/2016Lorenzo TallarigoInsiderBuy75,417GBX 4£3,016.68
10/25/2016Lorenzo TallarigoInsiderBuy77,864GBX 3£2,335.92
9/26/2016Lorenzo TallarigoInsiderBuy79,988GBX 3£2,399.64
8/25/2016Tallarigo ,LorenzoInsiderBuy62,257GBX 4£2,490.28
7/25/2016Tallarigo ,LorenzoInsiderBuy63,351GBX 4£2,534.04
6/24/2016Tallarigo ,LorenzoInsiderBuy62,847GBX 4£2,513.88
5/13/2016Diggle ,MartinInsiderBuy42,072GBX 5£2,103.60
5/12/2016Diggle ,MartinInsiderBuy45,428GBX 5£2,271.40
5/5/2016Diggle ,MartinInsiderBuy12,500GBX 6£750
5/4/2016Diggle ,MartinInsiderBuy44,689GBX 6£2,681.34
5/3/2016Diggle ,MartinInsiderBuy317,382GBX 6£19,042.92
4/29/2016Nolan,PeterInsiderBuy359,925GBX 6£21,595.50
4/22/2016Tallarigo ,LorenzoInsiderBuy41,083GBX 6£2,464.98
3/24/2016Tallarigo ,LorenzoInsiderBuy41,550GBX 6£2,493
2/26/2016Diggle ,MartinInsiderBuy29,345GBX 7£2,054.15
2/25/2016Tallarigo ,LorenzoInsiderBuy36,370GBX 7£2,545.90
2/24/2016Diggle ,MartinInsiderBuy46,693GBX 6£2,801.58
7/1/2015Diggle ,MartinInsiderBuy284,439GBX 0.09£256
6/30/2015Diggle ,MartinInsiderBuy775,000GBX 0.09£697.50
6/19/2015Diggle ,MartinInsiderBuy225,000GBX 0.08£180
6/12/2015Martin DiggleInsiderBuy283,978GBX 9.01£25,586.42
6/11/2015Martin DiggleInsiderBuy416,022GBX 9£37,441.98
6/9/2015Daniel SolandInsiderBuy500,000GBX 9.45£47,250
5/21/2015Andrew HeathInsiderBuy100,000GBX 10.60£10,600
5/19/2015Tim WattsInsiderBuy194,174GBX 10.30£19,999.92
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Oxford BioMedica plc (LON OXB)

Source:
DateHeadline
Is Oxford BioMedica PLC’s (LSE:OXB) Balance Sheet Strong Enough To Weather A Storm?Is Oxford BioMedica PLC’s (LSE:OXB) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 10 at 9:33 AM
OXB to present at Jefferies Healthcare Conference - London South East (blog)OXB to present at Jefferies Healthcare Conference - London South East (blog)
www.lse.co.uk - November 9 at 3:27 PM
Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL - GlobeNewswire (press release)Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL - GlobeNewswire (press release)
globenewswire.com - November 1 at 7:23 AM
Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCLOxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL
feeds.benzinga.com - October 31 at 12:44 PM
Oxford BioMedica plc (OXB) Insider Purchases £2,739.24 in StockOxford BioMedica plc (OXB) Insider Purchases £2,739.24 in Stock
www.americanbankingnews.com - October 23 at 1:32 PM
Andrew Heath Acquires 110,511 Shares of Oxford BioMedica plc (OXB) StockAndrew Heath Acquires 110,511 Shares of Oxford BioMedica plc (OXB) Stock
www.americanbankingnews.com - September 26 at 1:28 PM
Oxford BioMedica plc (OXB) Now Covered by Peel HuntOxford BioMedica plc (OXB) Now Covered by Peel Hunt
www.americanbankingnews.com - September 24 at 6:32 PM
Lorenzo Tallarigo Buys 29,685 Shares of Oxford BioMedica plc (OXB) StockLorenzo Tallarigo Buys 29,685 Shares of Oxford BioMedica plc (OXB) Stock
www.americanbankingnews.com - September 22 at 10:27 AM
Oxford BioMedica plc (OXB) Insider Martin Diggle Acquires 100,000 SharesOxford BioMedica plc (OXB) Insider Martin Diggle Acquires 100,000 Shares
www.americanbankingnews.com - September 15 at 10:27 AM
Oxford BioMedica plc (OXB) Releases  Earnings ResultsOxford BioMedica plc (OXB) Releases Earnings Results
www.americanbankingnews.com - September 11 at 7:12 AM
Oxford BioMedica plc (OXB) Insider Martin Diggle Sells 2,377,600 SharesOxford BioMedica plc (OXB) Insider Martin Diggle Sells 2,377,600 Shares
www.americanbankingnews.com - September 5 at 10:34 AM
Insider Buying: Oxford BioMedica plc (OXB) Insider Buys 320,000 Shares of StockInsider Buying: Oxford BioMedica plc (OXB) Insider Buys 320,000 Shares of Stock
www.americanbankingnews.com - September 5 at 10:34 AM
Oxford BioMedica plc (OXB) Scheduled to Post Earnings on MondayOxford BioMedica plc (OXB) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - September 4 at 2:22 AM
Oxford BioMedica plc (LON:OXB) Given New GBX 8.70 Price Target at N+1 SingerOxford BioMedica plc (LON:OXB) Given New GBX 8.70 Price Target at N+1 Singer
www.americanbankingnews.com - July 27 at 11:22 AM
Peter Nolan Buys 249,687 Shares of Oxford BioMedica plc (LON:OXB) StockPeter Nolan Buys 249,687 Shares of Oxford BioMedica plc (LON:OXB) Stock
www.americanbankingnews.com - July 17 at 11:29 AM
Insider Buying: Oxford BioMedica plc (OXB) Insider Buys 660,000 Shares of StockInsider Buying: Oxford BioMedica plc (OXB) Insider Buys 660,000 Shares of Stock
www.americanbankingnews.com - July 14 at 1:56 PM
Oxford BioMedica plcs (LON:OXB) "Not Rated" Rating Reaffirmed at Shore CapitalOxford BioMedica plc's (LON:OXB) "Not Rated" Rating Reaffirmed at Shore Capital
www.americanbankingnews.com - July 13 at 3:10 PM
Oxford BioMedica plc (LON:OXB) Stock Rating Reaffirmed by N+1 SingerOxford BioMedica plc (LON:OXB) Stock Rating Reaffirmed by N+1 Singer
www.americanbankingnews.com - July 9 at 7:30 AM
Investors Chronicle: Bellway, M&C Saatchi, Oxford Biomedica - Financial TimesInvestors Chronicle: Bellway, M&C Saatchi, Oxford Biomedica - Financial Times
www.ft.com - March 25 at 8:51 AM
[$$] Investors Chronicle: Bellway, M&C Saatchi, Oxford Biomedica[$$] Investors Chronicle: Bellway, M&C Saatchi, Oxford Biomedica
www.ft.com - March 24 at 6:58 PM
Oxford BioMedicas (OXBDF) CEO John Dawson on Q4 2016 Results - Earnings Call TranscriptOxford BioMedica's (OXBDF) CEO John Dawson on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 17 at 12:52 AM
UK STOCKS-Factors to watch on March 16UK STOCKS-Factors to watch on March 16
www.reuters.com - March 16 at 8:44 AM
Full Year 2016 Oxford BioMedica PLC Earnings Release - Before Market OpenFull Year 2016 Oxford BioMedica PLC Earnings Release - Before Market Open
biz.yahoo.com - March 16 at 8:44 AM
Director Dealings / Market Share Purchase - London South East (registration) (blog)Director Dealings / Market Share Purchase - London South East (registration) (blog)
www.lse.co.uk - January 25 at 5:56 AM
Findings Reported by Novartis on CTL-019 at ASH - London South East (registration) (blog)Findings Reported by Novartis on CTL-019 at ASH - London South East (registration) (blog)
www.lse.co.uk - December 5 at 7:03 PM
Result of General Meeting and Directors Dealing - London South East (registration) (blog)Result of General Meeting and Directors Dealing - London South East (registration) (blog)
www.lse.co.uk - September 30 at 6:43 PM

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Oxford BioMedica plc (LON OXB) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.